MiMedx Buys Sanara MedTech to Nearly Double Surgical Revenue
MiMedx agrees to buy Sanara MedTech for $35/share in a $350M cash-and-stock deal to nearly double surgical revenue. 2027 sales seen over $400M.
/ 2 items
MiMedx agrees to buy Sanara MedTech for $35/share in a $350M cash-and-stock deal to nearly double surgical revenue. 2027 sales seen over $400M.
BTIG maintains $9 price target on Organogenesis but reduces 2026 confidence after CMS delays skin substitute coverage rules, creating regulatory uncertainty for the wound care company.